Rebecca Rathburn, APRN
Acute Care · Boston, MANPI 1881271963
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (40.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Gilead at 45.8% of the total. Reporting peaked in 2024 at $9,015 and has fallen 89.9% since, to $907 in 2025. Among acute care clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $116.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Genentech USA, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$871
- Eisai Inc.$507
- Ipsen Bioscience Inc.$486
- plus $1K from 11 others
Across 15 payments — averaging $124.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Consulting fees$2,32018%
- Travel & lodging$5,04740%
- Food & beverage$4,87439%
- Education$3173%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 28 | $5,746 |
| Genentech USA, Inc. | 9 | $1,977 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $1,484 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $871 |
| Eisai Inc. | 7 | $507 |
| Ipsen Bioscience Inc. | 1 | $486 |
| Madrigal Pharmaceuticals | 2 | $271 |
| Novo Nordisk | 2 | $240 |
| AstraZeneca | 2 | $230 |
| Ipsen Biopharmaceuticals, Inc | 2 | $177 |
| Intra-sana Laboratories | 1 | $158 |
| Genentech, Inc. | 1 | $111 |
| Mallinckrodt Hospital Products Inc. | 1 | $109 |
| Exact Sciences | 1 | $70 |
| Intercept Pharmaceuticals, Inc. | 2 | $49 |
| W. L. Gore & Associates, Inc. | 2 | $38 |
| AbbVie | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,557 in reported general payments places this provider in the 95th percentile of 307 acute care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 13 | $304,522 |
| XifaxanRifaximin | 75 | $237,166 |
| RezdiffraResmetirom | 14 | $71,518 |
| Ursodiol | 62 | $12,666 |
| Mycophenolate Mofetil | 21 | $1,369 |
| Tacrolimus | 11 | $1,332 |
| Lactulose | 36 | $1,142 |
| Azathioprine | 20 | $815 |
| Spironolactone | 55 | $736 |
| Cyproheptadine Hcl | 22 | $325 |
| Pantoprazole Sodium | 31 | $306 |
| Furosemide | 75 | $242 |
| Baclofen | 17 | $215 |
| Ondansetron OdtOndansetron | 18 | $158 |
| Trazodone Hcl | 23 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $5,746 | $304,52213 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $871 | $237,16675 claims |
| Madrigal PharmaceuticalsRezdiffra | $271 | $71,51814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 307 acute care providers in Massachusetts.
Other acute care in Boston
- Bridgid JosephBoston$110K
- Pamela CalareseBoston$106K
- Kimberly GuiboneBoston$86K
- Dawn NaylorBoston$13K
- Morgan BowdenBoston$11K
- Javier RiveraBoston$11K
- Linda OrdwayBoston$7K
- Rebecca LongoBoston$7K
- Erin PearsonBoston$4K
- Dawn ResurreccionBoston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.